Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leucine-rich repeat kinase 2 inhibitor - Cerevel therapeutics

Next Previous
Search
Drug Profile

Leucine-rich repeat kinase 2 inhibitor - Cerevel therapeutics

Alternative Names: LRRK2 Inhibitor- Cerevel Therapeutics

Latest Information Update: 05 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics
  • Class Antiparkinsonians
  • Mechanism of Action LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
  • 31 Dec 2021 Cerevel Therapeutics has patent protection for leucine-rich repeat kinase 2 inhibitor in the United States, foreign jurisdictions, including Canada, Japan and in various member states of the European Patent Office prior to December 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top